Hit Expansion of a Noncovalent SARS-CoV‑2 Main Protease Inhibitor

Inhibition of the SARS-CoV-2 main protease (Mpro) is a major focus of drug discovery efforts against COVID-19. Here we report a hit expansion of non-covalent inhibitors of Mpro. Starting from a recently discovered scaffold (The COVID Moonshot Consortium. Open Science Discovery of Oral Non-Covalent S...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ACS pharmacology & translational science 2022-04, Vol.5 (4), p.255-265
Hauptverfasser:	Glaser, Jens, Sedova, Ada, Galanie, Stephanie, Kneller, Daniel W, Davidson, Russell B, Maradzike, Elvis, Del Galdo, Sara, Labbé, Audrey, Hsu, Darren J, Agarwal, Rupesh, Bykov, Dmytro, Tharrington, Arnold, Parks, Jerry M, Smith, Dayle M. A, Daidone, Isabella, Coates, Leighton, Kovalevsky, Andrey, Smith, Jeremy C
Format:	Artikel
Sprache:	eng
Schlagworte:	60 APPLIED LIFE SCIENCES antiviral therapeutics drug discovery hit expansion main protease inhibitor SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!